SAN ANTONIO, TX—Brexpiprazole was efficacious in the maintenance treatment of patients with acute schizophrenia who met stability criteria, improving and maintaining psychosocial and occupational functioning over 52 weeks, according to findings from a randomized, double-blind, placebo-controlled efficacy, safety, and tolerability study presented at the U.S. Psychiatric & Mental Health Congress.
"While some akathisia was observed in the stabilization phase, brexpiprazole was overall reasonably tolerated,” reported lead study author Catherine Weiss, PhD, of Otsuka Pharmaceutical Development & Commercialization, Inc., in Princeton, NJ, and coauthors.
However, the analysis was based on a small number of patients, “mostly due to early termination of the study following the interim analysis,” they cautioned.